Clinical - stage Biotech
Search documents
Stride (LRN) Securities Class Action Pending Over Enrollment Drop, Compliance Allegations -- Hagens Berman
Prnewswire· 2025-11-26 13:50
Core Viewpoint - Stride, Inc. is facing a securities class action lawsuit from shareholders due to significant operational and compliance challenges that have led to a sharp decline in its stock price [1] Company Overview - Stride, Inc. is one of the largest providers of online educational services in the United States [1] Legal Proceedings - Hagens Berman, a prominent shareholder rights law firm, is investigating legal claims against Stride and its executives, urging affected investors to report their losses [2] - The class action lawsuit covers the period from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline set for January 12, 2026 [3] Allegations - The lawsuit focuses on Stride's misleading assurances regarding its business model and enrollment figures, particularly after the cancellation of a contract with Gallup-McKinley [3] - Allegations include inflated student enrollment numbers through "ghost students," increased student-to-teacher ratios, and insufficiently licensed teachers, all aimed at inflating stock values [4][8] Impact on Enrollment - Stride reported that "poor customer experience" led to an estimated loss of 10,000 to 15,000 enrollments [5] Financial Forecast - The company has forecasted a sales growth of only 5% for 2026, a significant decline from the previous five years' annualized sales growth of 19%, raising concerns among investors [6] Investigation Focus - The investigation aims to determine the extent of company leadership's awareness of operational and compliance deficiencies prior to public disclosures and whether these misrepresentations constitute securities fraud [7]
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy
Prnewswire· 2025-11-03 14:04
Core Viewpoint - Tharimmune, Inc. has announced a private placement offering to raise approximately $540 million through the sale of common stock at a price of $3.075 per share, aimed at acquiring Canton Coin and supporting its digital asset treasury strategy [1][3][4]. Group 1: Offering Details - The private placement is expected to close around November 6, 2025, pending customary closing conditions [3]. - The offering involves participation from notable investors including ARK Invest, Bitwave, and the Canton Foundation, which oversees the Canton Network [2][6]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to acquire Canton Coin, a utility token for the Canton Network, and for general corporate purposes [3][4]. - Tharimmune plans to operate as a Super Validator on the Canton Network to generate additional CC tokens [3][4]. Group 3: Strategic Vision - Tharimmune believes that the Canton Network's blockchain technology is transforming financial infrastructure by enhancing programmability, privacy, and interoperability [4][5]. - The company aims to implement a diverse strategy that includes CC acquisition and the development of applications on the Canton Network to drive institutional utility and scalability [4][5]. Group 4: Management and Leadership - Mark Wendland has been appointed as CEO to oversee the digital asset treasury strategy, while Mark Toomey will serve as President [8]. - Both leaders bring extensive experience in operational leadership and global financial markets [8][9]. Group 5: Market Context - The Canton Network is noted for its ability to connect trusted institutions on a secure blockchain, with significant assets and support from major financial players [5]. - As of September 30, 2025, the Canton Network recorded over 500,000 daily transactions, showcasing its scalability [9].